)
Visual21 Nov 2025
Data center suppliers
Intellia Therapeutics (NTLA) investor relations material
Intellia Therapeutics Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary6 Nov, 2025
Executive summary
Lead in vivo programs for hereditary angioedema (HAE) and ATTR amyloidosis advanced, with lonvo-z Phase 3 HAELO trial fully enrolled and topline data expected mid-2026; commercial launch targeted for 2027.
Nex-z Phase 3 trials (MAGNITUDE and MAGNITUDE-2) for ATTR amyloidosis placed on FDA clinical hold after a patient death linked to liver complications; investigation ongoing and milestone guidance suspended pending regulatory alignment.
Strategic restructuring in January 2025 prioritized core programs, reduced workforce by 27%, and consolidated real estate, resulting in significant non-recurring charges.
Longer-term Phase 1/2 data for both nex-z and lonvo-z to be presented at major scientific meetings in November 2025.
Financial highlights
Cash, cash equivalents, and marketable securities totaled $669.9M as of September 30, 2025, down from $861.7M at year-end 2024.
Collaboration revenue for the nine months ended September 30, 2025 was $44.7M, nearly flat year-over-year; Q3 2025 revenue rose to $13.8M from $9.1M in Q3 2024.
Net loss for the nine months ended September 30, 2025 was $316.9M, an improvement from $390.1M in the prior year period; Q3 2025 net loss narrowed to $101.3M from $135.7M in Q3 2024.
Research and development expenses decreased by $49.2M year-over-year to $300.2M for the nine months ended September 30, 2025; Q3 2025 R&D expenses were $94.7M, down from $123.4M in Q3 2024.
Raised $114.5M in net equity proceeds during Q3 2025 via ATM program; $117.7M remains available under the program.
Outlook and guidance
Cash runway expected to fund operations into mid-2027 and through anticipated U.S. commercial launch of lonvo-z for HAE.
HAELO Phase 3 topline data for lonvo-z expected by mid-2026; BLA submission planned for 2H26.
Expenses projected to decrease in 2025 due to restructuring and program prioritization.
Milestone guidance for nex-z suspended pending resolution of FDA clinical hold.
Nex-z clinical hold: risk mitigation plan details
Lonvo-z HAELO trial: factors for rapid enrollment
Cash runway extension: drivers and assumptions
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Intellia Therapeutics earnings date
Q4 202526 Feb, 2026
Next Intellia Therapeutics earnings date
Q4 202526 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's therapies are based on a targeted genome editing platform, including CRISPR/Cas9 and proprietary next-generation programmable nucleases (PNs), which can induce a range of large deletions, substitutions or insertions across a target gene. The CRISPR/Cas9 genome editing technology has been shown to be effective in editing genomes in multiple cell types and organisms. Intellia Therapeutics was founded in 2013 and is based in Cambridge, Massachusetts.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage